Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement C1 Inhibitor Protein | 5 | 2014 | 6 | 1.510 |
Why?
|
| Angioedemas, Hereditary | 4 | 2013 | 5 | 1.400 |
Why?
|
| Cytomegalovirus Infections | 6 | 2019 | 70 | 0.960 |
Why?
|
| Kidney Transplantation | 6 | 2010 | 267 | 0.810 |
Why?
|
| Pancreas Transplantation | 3 | 2010 | 21 | 0.630 |
Why?
|
| Antiviral Agents | 5 | 2019 | 317 | 0.570 |
Why?
|
| Organ Transplantation | 3 | 2019 | 51 | 0.450 |
Why?
|
| Laryngeal Edema | 1 | 2013 | 4 | 0.450 |
Why?
|
| Complement Inactivating Agents | 1 | 2013 | 13 | 0.420 |
Why?
|
| Hereditary Angioedema Types I and II | 1 | 2013 | 1 | 0.420 |
Why?
|
| Graft Rejection | 4 | 2010 | 259 | 0.410 |
Why?
|
| Treatment Failure | 1 | 2010 | 189 | 0.340 |
Why?
|
| Ribonucleosides | 2 | 2019 | 2 | 0.330 |
Why?
|
| Benzimidazoles | 2 | 2019 | 59 | 0.310 |
Why?
|
| Pregnancy Complications | 1 | 2013 | 392 | 0.300 |
Why?
|
| Islets of Langerhans | 1 | 2005 | 267 | 0.220 |
Why?
|
| Gene Silencing | 1 | 2005 | 379 | 0.210 |
Why?
|
| Celiac Disease | 1 | 2002 | 17 | 0.210 |
Why?
|
| Drainage | 1 | 2002 | 147 | 0.190 |
Why?
|
| Postoperative Complications | 1 | 2007 | 1142 | 0.170 |
Why?
|
| RNA, Small Interfering | 1 | 2005 | 854 | 0.170 |
Why?
|
| Viremia | 1 | 2019 | 44 | 0.160 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 89 | 0.160 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 95 | 0.150 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2018 | 11 | 0.150 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 51 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 603 | 0.140 |
Why?
|
| Ganciclovir | 2 | 2007 | 20 | 0.140 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2018 | 88 | 0.140 |
Why?
|
| Graft Survival | 2 | 2010 | 279 | 0.140 |
Why?
|
| Filtration | 2 | 2013 | 22 | 0.130 |
Why?
|
| Humans | 16 | 2019 | 59810 | 0.130 |
Why?
|
| Adult | 8 | 2019 | 15882 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2013 | 5205 | 0.120 |
Why?
|
| Nanotechnology | 2 | 2013 | 128 | 0.120 |
Why?
|
| Complement Pathway, Mannose-Binding Lectin | 1 | 2014 | 2 | 0.120 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2014 | 4 | 0.120 |
Why?
|
| Complement Pathway, Classical | 1 | 2014 | 23 | 0.120 |
Why?
|
| Transplantation, Homologous | 2 | 2005 | 234 | 0.110 |
Why?
|
| Neutropenia | 2 | 2019 | 66 | 0.110 |
Why?
|
| Premedication | 1 | 2012 | 17 | 0.100 |
Why?
|
| Pregnancy Outcome | 1 | 2013 | 189 | 0.090 |
Why?
|
| Inflammation | 1 | 2018 | 1106 | 0.090 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 139 | 0.090 |
Why?
|
| Antilymphocyte Serum | 1 | 2010 | 21 | 0.090 |
Why?
|
| Female | 8 | 2019 | 31095 | 0.090 |
Why?
|
| Proteinuria | 1 | 2010 | 37 | 0.090 |
Why?
|
| Mycophenolic Acid | 1 | 2010 | 32 | 0.090 |
Why?
|
| Renal Replacement Therapy | 1 | 2010 | 23 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 95 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 1030 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2010 | 133 | 0.080 |
Why?
|
| Adolescent | 3 | 2019 | 5939 | 0.080 |
Why?
|
| Body Weight | 1 | 2010 | 381 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 303 | 0.080 |
Why?
|
| Child, Preschool | 1 | 2013 | 1843 | 0.070 |
Why?
|
| Biomarkers | 2 | 2010 | 1205 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 707 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 328 | 0.070 |
Why?
|
| Child | 2 | 2013 | 4324 | 0.070 |
Why?
|
| Pregnancy | 1 | 2013 | 2359 | 0.060 |
Why?
|
| Virus Replication | 1 | 2007 | 306 | 0.060 |
Why?
|
| Middle Aged | 5 | 2019 | 16400 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 798 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2007 | 192 | 0.060 |
Why?
|
| Fetal Proteins | 1 | 2004 | 11 | 0.060 |
Why?
|
| Receptors, Complement 3d | 1 | 2004 | 18 | 0.060 |
Why?
|
| Male | 6 | 2019 | 27766 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 880 | 0.050 |
Why?
|
| Comorbidity | 1 | 2007 | 1091 | 0.050 |
Why?
|
| Ischemia | 1 | 2005 | 193 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 1918 | 0.050 |
Why?
|
| Kidney | 1 | 2005 | 394 | 0.050 |
Why?
|
| Time Factors | 1 | 2010 | 3590 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2004 | 183 | 0.050 |
Why?
|
| Anastomosis, Surgical | 1 | 2002 | 97 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 442 | 0.050 |
Why?
|
| Insulin | 1 | 2005 | 689 | 0.050 |
Why?
|
| Young Adult | 3 | 2019 | 4363 | 0.050 |
Why?
|
| Dysgeusia | 1 | 2019 | 2 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 17 | 0.040 |
Why?
|
| Virus Activation | 1 | 2019 | 25 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 44 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 761 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2019 | 31 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 75 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2005 | 744 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2019 | 158 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 678 | 0.040 |
Why?
|
| Animals | 3 | 2018 | 19717 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2018 | 462 | 0.030 |
Why?
|
| Mice | 2 | 2005 | 10305 | 0.030 |
Why?
|
| CD55 Antigens | 1 | 2014 | 2 | 0.030 |
Why?
|
| CD59 Antigens | 1 | 2014 | 3 | 0.030 |
Why?
|
| Complement C5 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Erythrocyte Membrane | 1 | 2014 | 24 | 0.030 |
Why?
|
| Complement Pathway, Alternative | 1 | 2014 | 27 | 0.030 |
Why?
|
| Complement C3 | 1 | 2014 | 61 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 909 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 96 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 92 | 0.030 |
Why?
|
| Apoptosis | 1 | 2018 | 1040 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 223 | 0.020 |
Why?
|
| United States | 1 | 2005 | 7570 | 0.020 |
Why?
|
| Aged | 2 | 2019 | 13461 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 125 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 258 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 498 | 0.020 |
Why?
|
| Cohort Effect | 1 | 2007 | 2 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2007 | 344 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2005 | 34 | 0.020 |
Why?
|
| Reperfusion | 1 | 2005 | 37 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2004 | 16 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2004 | 36 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2004 | 65 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 97 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2004 | 108 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2004 | 120 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 193 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2004 | 274 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2004 | 528 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2004 | 354 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 397 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 664 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 502 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 5149 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 552 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 1379 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1559 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 968 | 0.010 |
Why?
|
| Models, Biological | 1 | 2004 | 1141 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2007 | 6041 | 0.010 |
Why?
|